Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

Mar 21, 2016

Overview:Valvular heart disease (VHD) is associated with a higher incidence of thromboembolic events, regardless of the underlying cardiac rhythm [1]. Atrial fibrillation (AF) is associated with a higher incidence of thromboembolic events in patients with rheumatic mitral stenosis or in... more

Rivaroxaban not FDA approved for the risk reduction of secondary CV events in patients with ACS

Apr 28, 2017

Overview:By Professor Juan Tamargo The FDA's Cardiovascular and Renal Drugs Advisory Committee declined to approve (6-4, with one abstention) to approve rivaroxaban for use in acute coronary syndromes (ACS). Despite positive results from the global, phase III ATLAS ACS 2-TIMI... more

Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: A systematic review and meta-analysis.

Jan 12, 2015

Overview:Background and knowledge gap Stable angina is a form of coronary artery disease. Its potential to progress requires the most appropriate treatment in order to reduce the incapacitating effect of an acute angina attack and to avoid long-term cardiovascular events.... more

Ticagrelor Added to Recommended Agents for MI

Apr 28, 2017

Overview:By Professor Juan Tamargo, Madrid, Spain The new update of the guideline for the management of patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI) of the the American Heart Association and the American College of Cardiology Foundation recommended prasugrel,... more

The EMA approves ivabradine for the treatment of chronic heart failure

Apr 28, 2017

Overview:By Professor Juan Tamargo, Madrid, Spain The European Medicines Agency (EMA) has approved ivabradine for the treatment of chronic heart failure. This drug was licensed for stable angina since 2006. The EMA indicated that ivabradine it is suitable for patients... more

A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events–Reduction of Cholesterol to Key European Targets Trial.

Aug 17, 2015

Overview:The debate over the cholesterol hypothesis and statins has raged for decades. The early period following the onset of acute coronary syndrome represents a critical stage of coronary heart disease, with a high risk of recurrent events and deaths. The... more

Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project).

Mar 17, 2015

Overview:Aim of the Study TWICE project study compared the anticipated inhibition of platelet aggregation (IPA) of ticagrelor twice-daily to clopidogrel once-daily using patients’ adherence data. Methods Using an electronically compiled dosing history, data of 5014 patients prescribed cardiovascular medications (primarily... more

Multaq (dronedarone): Drug Safety Communication

Apr 28, 2017

Overview:By Professor Juan Tamargo, Madrid, Spain The U.S. Food and Drug Administration (FDA) has completed a safety review of the drug Multaq (dronedarone). Data from two clinical trials, PALLAS and ATHENA, showed that Multaq increased the risk of serious cardiovascular... more

Myocardial infarction with non-obstructive coronary arteries (MINOCA)

Jul 25, 2017

Overview:By Professor Stefan Agewall A sizeable proportion of MIs, ranging between 1% and 14%, occur in the absence of obstructive coronary artery disease. The diagnostic criteria of MINOCA fulfill the universal criteria of myocardial infarction, but without coronary artery stenosis... more

Significance of LOX-1 in cardiovascular function and its application for therapeutic diagnosis

Apr 28, 2017

Overview:Tatsuya Sawamura, MD, PhD Professor, Department of Physiology, Shinshu University LDL is a “bad” cholesterol in the blood that is involved in the progression of arteriosclerosis. Particular focus has been placed on modified LDL, such as LDL that has been... more